Cases

cancer
A large international pharmaceutical company will apply for the Class 1 reimbursement of a novel therapy, CAR-T, to treat patients with diffuse large B-cell lymphoma (DLBCL). The customer has asked...
CAR T-cell therapy
A large international pharmaceutical company will apply for the Class 1 reimbursement of a novel therapy, CAR-T, to treat patients with paediatric acute lymphoblastic leukaemia (pALL).  The...
Patiënt blood management in België
Patient blood management (PBM) becomes increasingly important for hospitals, as policies and guidelines are developed. The European Commission recently published a practical implementation guide for...
Novartis Logo
Novartis, a large international pharmaceutical company applied for the Class 1 reimbursement of the new drug, Rydapt, to treat patients with acute myeloid leukaemia who are FLT3 mutation-positive....
Cost Effectiveness and Budget Impact
A large international pharmaceutical company was applying for the reimbursement of a new indication of an existing product.  As the reimbursement request was for an orphan drug, a cost-...
Curando Logo
A major change in the past year was the ‘Curando HOP’ project coached by hict, with the aim of harmonisation and optimisation of all the processes. In line with this project a second project...
Default Image - Pharma
Performing a health-economic evaluation (budget impact analysis) of a proposed adaptation of the reimbursement criteria for certain implants in Belgium.
Client logo for Vlaamse Logo's
Logo stands for LOkaal GezondheidsOverleg (local deliberation on health). Logos are geographically defined networks wherein different organisations collaborate to execute the Flemish preventive care...
Novartis logo
Novartis, a large international pharmaceutical company had applied for Class 1 reimbursement of Jakavi for adult patients with myelofibrosis.  The company asked hict for support...
Ezelstraat 69 | B- 8000 Brugge | Belgium | Phone: +32.50.33.33.40 | Fax: +32.50.33.33.39 | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: info@hict.com